📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
48 announcements match the current filters (relevance ≥ 5).
Zota Health Care Expands Davaindia Network to 2,331 Stores with 276 New Openings in Q3FY26
Zota Health Care has reported a robust expansion of its Davaindia retail chain, adding 276 new stores during Q3FY26. This brings the total store count to 2,331 as of December 31, 2025, up from 2,055 at the end of the previous quarter. The growth was heavily weighted toward Company Owned Company Operated (COCO) stores, which saw 231 new additions. This aggressive scaling strategy indicates the company's commitment to increasing its market share in the generic pharmacy retail segment.
Key Highlights
Total Davaindia store count reached 2,331 as of December 31, 2025
Added 276 new stores during the Q3FY26 period
COCO stores increased by 231 units to a total of 1,438
FOFO stores grew by 45 units to reach a total of 893
Expansion reflects a strong focus on the COCO model managed by its wholly owned subsidiary
👀 What to Watch
Investors should view this rapid footprint expansion as a positive lead indicator for future revenue growth. Monitor upcoming earnings to see if the increased store count translates into improved operating leverage and profitability.
Zota Health Care Raises Rs 350 Crores via QIP at Rs 1,535 Per Share
Zota Health Care has successfully completed a Rs 350 crore fundraise through a Qualified Institutional Placement (QIP), allotting 22.80 lakh shares at Rs 1,535 each. The issue attracted marquee investors including White Oak Capital, 360 ONE, and Prashant Jain-led 3P Investment Managers. The proceeds are primarily earmarked for the aggressive expansion of the 'Davaindia' generic pharmacy chain, aiming to scale from 2,253 stores to over 5,000 stores by March 2029. This capital infusion significantly strengthens the company's balance sheet for its next phase of growth in the affordable medicine segment.
Key Highlights
Raised Rs 350 crores by issuing 22,80,130 equity shares at a price of Rs 1,535 per share
Participation from marquee investors including Valiant Partners, White Oak Capital, and 3P Investment Managers
Funds to drive expansion of Davaindia stores from current 2,253 to over 5,000 by March 2029
Current store network includes 1,373 Company-Owned (COCO) and 880 Franchisee-Owned (FOFO) outlets
Proceeds also allocated for working capital requirements and general corporate purposes
👀 What to Watch
The participation of high-profile institutional investors provides a strong valuation benchmark and validation of the Davaindia business model. Investors should monitor the company's ability to maintain per-store profitability while doubling its store count over the next four years.
Zota Health Care Allots 6.02 Lakh Equity Shares on Warrant Conversion at Rs 820/share
Zota Health Care Limited has successfully completed the conversion of its remaining 6,02,500 warrants into equity shares at an issue price of Rs 820 per share. This final tranche of conversion has brought in approximately Rs 37.05 crore in warrant exercise money from non-promoter institutional investors. Following this allotment, the company's paid-up equity capital has increased to Rs 33.77 crore, representing 3,37,73,901 shares. With this action, there are no outstanding warrants left from the original February 2025 preferential issuance.
Key Highlights
Allotment of 6,02,500 equity shares at a premium price of Rs 820 per share
Total capital inflow of Rs 37.05 crore received as 75% warrant exercise money
Key institutional allottees include 3P India Equity Fund and Valiant India Opportunities Ltd
Total paid-up equity shares increased from 3.31 crore to 3.37 crore
Zero outstanding warrants remain from the original 7,52,500 warrants issued in Feb 2025
👀 What to Watch
The successful conversion of warrants at a significant premium by institutional investors signals strong external confidence in Zota's business model. Investors should monitor the company's upcoming quarterly results to see how this fresh capital is deployed for growth.
Zota Health Care Raises ₹350 Crore via QIP; Allots 22.8 Lakh Shares at ₹1,535 Each
Zota Health Care has successfully completed a Qualified Institutional Placement (QIP), raising approximately ₹350 crore. The company allotted 22.80 lakh equity shares to institutional investors at an issue price of ₹1,535 per share, which included a 4.97% discount to the floor price. This fundraise has increased the company's paid-up equity capital from ₹30.89 crore to ₹33.17 crore. The issue saw strong participation from marquee investors like Valiant Mauritius Partners and Ashoka Whiteoak, signaling high institutional confidence.
Key Highlights
Allotted 22,80,130 equity shares at ₹1,535 per share, aggregating to ₹349.99 crore.
The issue price includes a discount of ₹80.28 (4.97%) on the floor price.
Total paid-up equity share capital increased to 3,31,71,401 shares post-allotment.
Valiant Mauritius Partners (Offshore and Limited) emerged as the largest allottees, taking up over 42% of the issue.
Other major participants include Ashoka Whiteoak India Opportunities Fund (11.65%) and Sanshi Fund-I (7.14%).
👀 What to Watch
The successful capital raise and entry of high-quality institutional investors are positive indicators for the company's growth trajectory. Investors should monitor the company's upcoming quarterly results to see how this capital is deployed for expansion or debt reduction.
Zota Health Care Closes QIP to Raise ₹350 Crore at ₹1,535 Per Share
Zota Health Care Limited has successfully concluded its Qualified Institutions Placement (QIP) on December 17, 2025. The company approved the allotment of 22,80,130 equity shares to qualified institutional buyers at an issue price of ₹1,535 per share. This issue price includes a discount of 4.97% on the floor price of ₹1,615.28. The total capital raised through this placement is approximately ₹350 crore, which strengthens the company's balance sheet for future growth initiatives.
Key Highlights
Allotment of 22,80,130 equity shares of face value ₹10 each to eligible QIBs.
Issue price fixed at ₹1,535 per share, including a premium of ₹1,525.
Applied a discount of ₹80.28 per share (4.97%) on the floor price of ₹1,615.28.
Total fundraise size is approximately ₹350 crore.
The QIP process was completed within three days, opening on December 15 and closing on December 17, 2025.
👀 What to Watch
Investors should view the successful institutional fundraise as a sign of confidence in the company's growth prospects. Monitor the company's upcoming quarterly results to see how the fresh capital is deployed for expansion or debt reduction.
Zota Health Care Closes QIP; Allots 22.8 Lakh Shares at ₹1,535 Per Share
Zota Health Care has successfully concluded its Qualified Institutions Placement (QIP) on December 17, 2025. The company approved the allotment of 22,80,130 equity shares to qualified institutional buyers at an issue price of ₹1,535 per share. This price reflects a 4.97% discount to the floor price of ₹1,615.28 per share. The total fundraise amounts to approximately ₹350 crore, which strengthens the company's balance sheet for future growth initiatives.
Key Highlights
Allotment of 22,80,130 equity shares of face value ₹10 each to eligible QIBs
Issue price fixed at ₹1,535 per share, including a premium of ₹1,525
Applied a discount of ₹80.28 per share (4.97%) on the floor price of ₹1,615.28
The QIP issue period was open from December 15 to December 17, 2025
Total capital raised through the placement is approximately ₹350 crore
👀 What to Watch
The successful QIP at a minimal discount indicates strong institutional demand and provides the company with significant growth capital. Investors should monitor how the management deploys these funds to drive earnings growth.
Zota Health Care Launches QIP; Sets Floor Price at ₹1,615.28 Per Share
Zota Health Care Limited has officially launched its Qualified Institutions Placement (QIP) on December 15, 2025, following prior shareholder approval. The company has fixed the floor price for the issue at ₹1,615.28 per equity share, calculated as per SEBI regulations. The company also retains the option to offer a discount of up to 5% on this floor price to participating institutional buyers. This move is aimed at raising capital to support the company's strategic growth and financial requirements.
Key Highlights
QIP issue officially opened on December 15, 2025, following Fund-Raising Committee approval
Floor price for the equity shares fixed at ₹1,615.28 per share based on SEBI pricing formula
Company may offer a discretionary discount of up to 5% on the floor price for the issue
Relevant Date for the purpose of the QIP pricing is December 15, 2025
👀 What to Watch
Investors should monitor the final issue price and the profile of institutional investors participating in the QIP. While the issue will result in equity dilution, the capital infusion is expected to strengthen the company's growth prospects.
Zota Health Care Launches QIP; Sets Floor Price at ₹1,615.28 Per Share
Zota Health Care Limited has officially launched its Qualified Institutions Placement (QIP) to raise capital from institutional investors. The Fund-Raising Committee has fixed the floor price at ₹1,615.28 per equity share, based on SEBI pricing regulations. The company has the option to offer a discount of up to 5% on this floor price to eligible buyers. This capital raise follows shareholder approval obtained in late September 2025 and is intended to strengthen the company's financial standing.
Key Highlights
Floor price for the QIP is established at ₹1,615.28 per equity share.
The company may offer a maximum discount of 5% on the floor price at its discretion.
The 'Relevant Date' for the purpose of pricing the QIP is December 15, 2025.
The issue follows prior board approval on September 4 and shareholder approval on September 29, 2025.
👀 What to Watch
Investors should monitor the final issue price and the quality of institutional participants as a gauge of market confidence. While the fundraise will cause equity dilution, the capital infusion is generally positive for the company's growth trajectory.
